Navigation Links
New Data from Silence's Atu027 Anticancer Trial Published at ASCO
Date:5/16/2012

LONDON, May 17, 2012 /PRNewswire/ --

- Atu027, a First in Class RNAi Therapy, Demonstrates Potential

- Antitumour Activity in Cancer Patients and Possible Biomarker Identified

Silence Therapeutics to Announce New Data from Phase I Study of Atu027 in Solid Tumours At 2012 ASCO Annual Meeting

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, today announces that top line data from its ongoing Phase I trial of Atu027 show that of the 33 patients treated in the first 10 cohorts of the study, 10 patients experienced stable disease after three months. Two patients with neuroendocrine cancers had disease stabilisation for nine and 12 months respectively, including partial regression of liver metastases in one patient. Another patient with breast cancer demonstrated regression of liver metastases. Importantly, among various biomarkers tested, sVEGFR-1 plasma levels decreased significantly upon treatment further confirming a potential biological effect of Atu027.  

Silence will publish the latest data from its ongoing Phase I study of Atu027, its lead internal therapeutics candidate, at the 2012 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, Illinois, 1-5 June 2012. Further data from the ongoing Phase I Atu027 clinical study will also be the subject of a presentation with the following details:

Abstract Title: Anti-metastatic activity of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3): Final results of a phase I study in patients with advanced solid tumours. Abstract #: 98347 Presentation Date/Time: Mon, June 04, 2012 / 16:00 - 18:00 Location: Networking Lounge, Level 3, North Presenters: Klaus Giese [http://silence-therapeutics.com/about-us/man
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
3. Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer
4. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
5. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
6. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
7. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
8. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
9. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
10. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
11. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... MECHELEN, Belgium , May 17, 2013 ... ABBV ) announced today an extension of ... Galapagos will fund and complete a Phase 2 program ... progression into Phase 3.  Upon successful completion of the ... $50 million.  The terms of the collaboration extension are ...
(Date:5/16/2013)... , May 16, 2013  Today, the National ... Carolina House of Representatives recently approved a ... chemotherapy from charging patients higher out-of-pocket fees for newer, ... many of which have more severe side-effects. However, the ... of $300, which will continue to be a barrier ...
(Date:5/16/2013)... May 16, 2013  Amgen (NASDAQ: AMGN ) ... Tuesday, May 21, 2013, at the Sheraton New York Times ... at 10:00 a.m. Eastern Daylight Time. Joseph P. ... and Development at Amgen, will present at the conference. Live ... Calendar on Amgen,s website, www.amgen.com , under Investors. A ...
Breaking Medicine Technology:AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
(Date:5/19/2013)... Beach, Florida (PRWEB) May 19, 2013 ... and market access, is pleased to unveil a new ... show environment that provides a powerful array of real-time ... partners in the US and abroad. , HE-Xpo is ... will offer attendees the look and feel of being ...
(Date:5/18/2013)... COOLA, British Columbia (PRWEB) May 19, 2013 ... to Cooking” (published by iUniverse) , author Janet Hall Svisdahl’s ... delectable world recipes sure to make even the pickiest ... living peacefully, pleasurably and prayerfully,” she explains. , Found ... Spirit” are a wide range of delicious recipes, from fast ...
(Date:5/18/2013)... 2013 Also known as bariatric ... weight loss surgery that guarantees patients long-term weight loss. ... wishes to give readers a brief tutorial on this ... school at New York City’s Mount Sinai School of ... undertook a fellowship in Minimally Invasive Bariatric Surgery. He ...
(Date:5/18/2013)... -- Just a few extra cups of coffee each ... liver disease known as primary sclerosing cholangitis (PSC), a ... in Rochester, Minn., found that drinking coffee was associated ... can lead to cirrhosis of the liver, liver failure ... a cause-and-effect relationship. "While rare, PSC has ...
(Date:5/18/2013)... 2013 In a May 14, 2013 ... Mastectomy After Discovering Cancer Gene,” Fox News reported the ... learning that she carried a gene that doctors estimated ... and a 50 percent risk of ovarian cancer (go ... May 16, 2013 with a blog post entitled “A ...
Breaking Medicine News(10 mins):Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2
... recognized that certain areas in the brain,s left hemisphere enable ... out exactly how those areas divvy up the highly complex ... brain imaging made within the last 10 years have revealed ... not only on particular regions of the cerebral cortex, but ...
... decades-long leadership in the area of palliative care, the ... one of the first nationwide to earn advanced certification ... accrediting body in health care. The commission,s Gold ... effective last month. The University,s program is only the ...
... David Eastmond at the University of California, Riverside ... Ramazzini , an organization of international scholars who work ... the world. Founded as an independent, international academy ... Ramazzini is comprised of a select group of no ...
... sex more often than women do, but a new study suggests ... and sleep, more frequently than women do, as well. And ... every seven seconds, which would amount to more than 8,000 thoughts ... number of young men,s thought about sex stood at almost 19 ...
... By Jenifer Goodwin HealthDay Reporter , ... children with attention-deficit/hyperactivity disorder (ADHD) show abnormalities in certain ... Researchers performed functional MRIs (fMRIs) on 19 children aged ... the disorder while the children took a test in ...
... 2011 - Serious global discussions have begun in the lead-up ... and international agencies are asking what has been achieved, what ... after the deadline. Against this backdrop, a new paper published ... finds that "quick impact" strategies, which may have solved some ...
Cached Medicine News:Health News:How the brain strings words into sentences 2Health News:How the brain strings words into sentences 3Health News:How the brain strings words into sentences 4Health News:Rochester's Palliative Care Program achieves top national certification 2Health News:Rochester's Palliative Care Program achieves top national certification 3Health News:Study debunks stereotype that men think about sex all day long 2Health News:Study debunks stereotype that men think about sex all day long 3Health News:Study debunks stereotype that men think about sex all day long 4Health News:Brain Pathways Seem Disrupted in Kids With ADHD 2Health News:Brain Pathways Seem Disrupted in Kids With ADHD 3Health News:Good intentions may hamper progress in pursuit of global reproductive health and rights 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: